BLUEBERRIES MEDICAL CO - BBRRF STOCK NEWS

Blueberries Medical Corp. (OTC: BBRRF) reported financial results for the year ending December 31, 2022. The company generated revenues of $235,449, a significant increase of 70% over 2021 due to new product introductions like CBD isolate. Total current assets rose to $2,185,642 from $1,563,617, while total liabilities decreased to $1,886,394 from $2,159,134. The net loss narrowed to $1,467,876 from $5,147,012, driven by increased sales and cost reductions in various operational areas. Blueberries aims to achieve break-even sales levels and expand market reach with operations in Argentina and a new shipment to Australia. The CEO expressed cautious optimism as the company awaits regulatory changes in Colombia.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has successfully completed a non-brokered private placement, issuing 54,498,889 common shares at CAD$0.027 each, raising approximately CAD$1.47 million (US$1.1 million). The funds will enhance production capabilities, upgrade infrastructure, and expand business networks into Europe, the USA, and Australia. The company pivoted to extraction services, generating CAD$178,397 in revenue for the first nine months of 2022, while reducing operational costs. However, the company reported a net loss of CAD$1.47 million in the same period.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reports significant growth in Q2 2022, doubling revenues to $39,826, driven by extraction services. The shift towards extraction services and successful exports to Argentina support their strategic pivot. The company has established a partnership for GACP CUMSC certified CBD and THC strains and is exploring new markets with innovative water-soluble products. However, operational costs surged, leading to a net loss of $511,717, raising concerns about expense management despite revenue growth.

Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) announced significant strides in its operations, including over 60 kg of CBD and non-psychoactive product shipments to Argentina. The company expects annual sales exceeding $2.5 million for 2023. Additionally, Blueberries received Colombian licenses for psychoactive cannabis exports and partnered with YVY Life Sciences to enhance operations. Operational expenses have decreased significantly, with plans to complete a GMP-compliant extraction lab by Q1 2023. A debt extension worth C$1 million is also disclosed, with a related party transaction highlighted.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) released its Q1 2022 financial results, reporting revenues of $33,715, a significant increase compared to $23,120 in Q1 2021. Despite a gross profit of $13,918, the company incurred a net loss of $656,307, up from $590,325 a year earlier, primarily due to increased operational costs. The company is moving towards expanding revenues through new extraction services and partnerships in Latin America, while focusing on minimizing expenses and optimizing cash flow.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reported a 110% increase in revenue for the year ended December 31, 2021, totaling $138,747. The company faced challenges due to market conditions and regulatory impacts but anticipates growth following the approval of Decree 811 allowing exports of dried cannabis from Colombia. Despite an increase in revenues, the company incurred a substantial net loss of $5,147,012 and recognized significant impairments on assets totaling $3,388,518. The management is focused on cash management and establishing processing capabilities to drive future sales growth.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reported significant financial growth for the nine months ended September 30, 2021. Revenue surged by 339% to $173,886, up from $39,607 in the same period last year. Gross margin increased to 63%, while the company successfully reduced operating expenses by 55%, amounting to around $1,932,072. Notable achievements include the export of 150kg of CBD oil to Peru, marking its largest sale to date, and securing regulatory approval for new agricultural operations in Colombia. The company's cash position improved substantially following a private placement of $1.9 million.